Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab

We investigated risk factors for immune-related adverse events (irAEs) in patients treated with anti-programmed cell death protein1 antibody pembrolizumab. A retrospective medical record review was performed to identify all patients who received at least one dose of pembrolizumab at Samsung Medical...

Descripción completa

Detalles Bibliográficos
Autores principales: Eun, Yeonghee, Kim, In Young, Sun, Jong-Mu, Lee, Jeeyun, Cha, Hoon-Suk, Koh, Eun-Mi, Kim, Hyungjin, Lee, Jaejoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773778/
https://www.ncbi.nlm.nih.gov/pubmed/31575933
http://dx.doi.org/10.1038/s41598-019-50574-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773778/
https://www.ncbi.nlm.nih.gov/pubmed/31575933
http://dx.doi.org/10.1038/s41598-019-50574-6

Ejemplares similares